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Abstract
Evidence supporting the importance of assessment of mucosal healing in inflammatory bowel
disease has increased in the last years. Mucosal healing has been integrated in the assessment
of treatment efficacy in ulcerative colitis, but in Crohn's disease this thought has arised after bi-
ological agents have been evaluated in clinical trials. Although a validated definition of mucosal
healing still does not exist, its use is also assuming an increasingly important role in the follow-up
of individual patients in clinical practice. Corticosteroids induce mucosal healing in a small pro-
portion of patients with Crohn's disease and are of no benefit to maintain it. By contrast, muco-
sal healing in Crohn's disease can be achieved and maintained, with varying degrees of evidence
and success, with thiopurines and biological agents. In ulcerative colitis, the ability of cortico-
steroids to induce mucosal healing is well recognized. 5-aminosalicylates, thiopurines and bio-
logical agents are also able to induce mucosal healing and, additionally, to maintain it.
Mucosal healing assessment should be considered in clinical practice when symptoms persistMedical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands. Tel.:
.nl (G. D'Haens).
Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.
493Therapy and intestinal healing in IBDdespite therapy or when treatment discontinuation is being considered. Conversely, in patients
whose clinical remission is not associated with mucosal healing, intensification of treatment is
not currently recommended because of lack of evidence.
© 2012 Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation.Contents
1. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 493
2. How should mucosal healing be assessed and when should it be measured? . . . . . . . . . . . . . . . . . . . . . . 494
3. What drugs are most likely to produce mucosal healing? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495
3.1. Crohn's disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495
3.1.1. The mucosal healing capacities of drug therapies in Crohn's disease . . . . . . . . . . . . . . . . . . 495
3.2. Ulcerative colitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 497
3.2.1. The mucosal healing capacities of drug therapies in ulcerative colitis . . . . . . . . . . . . . . . . . 497
4. When to start treatment to achieve mucosal healing? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498
5. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 500
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5001. Introduction
Crohn's disease and ulcerative colitis, the two major forms of
idiopathic inflammatory bowel disease, are characterized by
the presence of inflammatory changes in the gut associated
with ulcerations of various sizes and depths. Crohn's disease
is frequently associated with complications, and surgery is
necessary in up to 70% of patients. Postoperative recurrence
is common, however, and repeated cycles of surgery-relapse
can lead to progressive and disabling loss of intestinal
function.1 As for ulcerative colitis, total proctocolectomy is
necessary in some patients with poorly controlled disease.
The management of inflammatory bowel disease has tra-
ditionally been aimed at improving the patient's symptoms,
but relatively little attention has been focused on the
longer-term impact of this endpoint or on its relation to en-
doscopically ascertained resolution of the mucosal lesions.
Thus, the scientific committee of ECCO has launched a
scientific workshop in 2010 that focused on this significant
clinical research question. The overall objective of this
workshop was to better understand and explore the impor-
tance of mucosal healing in inflammatory bowel disease.
The outcome of this workshop is presented into four parts:
Mechanisms of Intestinal Healing (Basic science), Measures
and Markers of Prediction to achieve, detect, and monitor
Intestinal Healing, Impact of Intestinal Healing on the Course
of IBD (Natural history), and Therapeutic Strategies to en-
hance Intestinal Healing (Therapy). This manuscript summa-
rizes current knowledge about therapeutic strategies to
enhance Intestinal Healing and highlights several key issues
that need to be addressed in future studies.
A host of indirect evidence indicates that the presence or
absence of mucosal healing is prognostically relevant. In a
Norwegian population-based cohort, mucosal healing was
found to have a significant influence on the outcome ofinflammatory bowel disease.2 In this study, 458 patients
with ulcerative colitis or Crohn's disease were assessed clin-
ically and endoscopically at baseline/the time of diagnosis
and 1 year and 5 years after diagnosis/later. The finding of
mucosal healing at the 1 year examination was associated
with reduced rates of surgery during long-term follow-up.
Results were confirmed during the 10-year follow-up of the
same cohort, thus highlight the potential benefits of mucosal
healing on surgical intervention rates.3 In Crohn's disease,
mucosal healing has been associated with longer-lasting
corticosteroid-free clinical remission,4 longer times to
clinical relapse,5 and reduced need for surgical intervention
and hospitalization.6,7 The concept of “deep remission” is a
recently introduced end point, which includes corticosteroid-
free clinical remission and mucosal healing. It has been intro-
duced and applied to patients with Crohn's disease on bio-
logics/immunomodulators who have no symptoms and
objective signs of inflammation.8
Also, in ulcerative colitis, mucosal healing has been asso-
ciated with a reduced risk of relapse9–11 and lower colect-
omy rates,12,13 but its importance does not end here. In
children and adolescents, it can often restore normal
growth, and in patients of all ages it may be associated
with reduced loss of important nutrients such as iron. Final-
ly, in theory at least it is thought to have potentially positive
effects on the risk of cancer.
For these reasons, more and more clinicians are now ask-
ing whether mucosal healing should be a therapeutic objec-
tive in patients with IBD, and if so, how this objective can be
achieved. This section will explore some of the fundamental
issues related to mucosal healing that have to be resolved—
beginning with the definition of the term itself. We will
also look at the therapeutic strategies most likely to achieve
and maintain this goal and its possible impact on therapeutic
decision making.
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when should it be measured?Mucosal healing is currently assessed on the basis of the
macroscopic appearance of the mucosa at ileocolonoscopy.
The term healing in this context does not imply the complete
absence of active inflammation. The term mucosal healing
falls within the boundaries of a broader concept, that of in-
testinal healing, which also includes histological, trans-
mural, and fistula healing. Endoscopically ascertained
mucosal healing is considered a surrogate efficacy end
point in clinical drug trials, and its use in clinical practice
is also increasing. And yet we still do not have a validated
definition of what this term means in patients with inflam-
matory bowel disease.
The endoscopic features of mucosal inflammation in a
patient with Crohn's disease include erythema, swelling,
nodularity, aphthoid ulcerations, ulcers of variable size and
depth, and strictures. In ulcerative colitis the inflamed muco-
sa presents at endoscopy with vascular congestion, erythema,
edema, granularity, friability, spontaneous bleeding, and
macroscopic ulcerations of variable size and depth. In light
of the complexity of these presentations, it is clear that any
meaningful endoscopic assessment of mucosal lesions in in-
flammatory bowel disease and their responses to therapeutic
interventions must be based on validated endoscopic indices
of disease activity.14,15
The endoscopic indices used thus far to grade mucosal
lesions in Crohn's disease and in ulcerative colitis have
been extensively discussed in another part (part B) of this
Workshop. In particular, the Crohn's Disease Endoscopic
Index of Severity (CDEIS)16 and the Simplified Endoscopic
Activity Score for Crohn's Disease (SES-CD)17 both have their
own strengths and weaknesses. They present lack of agree-
ment about cut-off values for endoscopic response/remission,
and do not provide a reliable estimate of the extension of the
disease. Furthermore, one of the main limitations of the
Rutgeerts score18 in the postoperative setting is the definition
of grade 2 recurrence, which is muchmore subjective than the
definitions of other grades. As a matter of fact, the definition
of mucosal healing usually employed in clinical trials and in
clinical practice is the disappearance of mucosal ulcerations.
This “black-or-white” approach has a number of shortcomings,
including a clear classification bias toward one specific type of
lesion. It leaves no space to for the concept of mucosal
(partial) improvement. The endoscopic disease activity indi-
ces developed for use in ulcerative colitis classify endoscopic
lesions as normal/near normal, improved, no change or
worse; assess the severity of bleeding without any consider-
ation ofmucosal ulcers (e.g., Baron score)19; or variably assess
the pattern of mucosal lesions (e.g., Mayo score).20 The Mayo
endoscopic score is used frequently, but distinguishes only
four grades of severity, andmild friability (score 1) is classified
as a sign of active disease rather than of mucosal healing. As
noted above, each of these indices has its own strengths and
weaknesses, but all are subject to interobserver variability,
and none has been fully validated with the notable exception
of the recently presented UCEIS (ulcerative colitis endoscopic
index of severity).21
Enrolment criteria have varied widely in the clinical trials
that have included mucosal healing as a marker of efficacy inthe assessments of conventional treatments for Crohn's dis-
ease. Study populations considered have entered the specif-
ic trial as active or quiescent disease, with “colonic or
ileocolonic involvement” and “presence of severe lesions”,
or “mucosal ulcerations”, or “mucosal ulcerations in at
least 2 intestinal segments and a CDEIS of more than 8” or
“active endoscopic inflammation”. Postsurgical populations
have been enrolled with “recurrent pre-anastomotic ileal
or colonic disease” or “severe refractory recurrence,” and
the endoscopic findings have been reported as scores or
with simple descriptive terms. As for mucosal healing, it
has been assessed at various time points, and its definition
is generally descriptive (e.g., normal appearing mucosa—
only scars, disappearance of all endoscopic lesions, disap-
pearance of any pathological findings, complete absence of
mucosal ulcerations, no ulcers) although in some cases it is
not defined at all.14,22 From a clinician's point of view, this
heterogeneity makes it difficult to compare among studies
and/or medications and should be made more uniform.
As for ulcerative colitis, mucosal healing has generally
been regarded as an important treatment goal, and endo-
scopic remission has been used as end point in trials focusing
the induction or maintenance of remission. The entry
criteria adopted in these studies vary from active symptoms,
with or without endoscopic confirmation, disease activity
indices or composite clinical and endoscopic disease activity
indices. In 2007 an expert consensus statement recom-
mended that complete mucosal healing (defined as
“absence of friability, blood, erosions and ulcers in all the vi-
sualized segments”) should be incorporated into the primary
end point of all trials on ulcerative colitis.15 Among the few
studies that have included an end point of this type, the
definitions have varied, from descriptive definitions (e.g.,
“rectal mucosa repaired with appearance of vascular pat-
tern” or “normal sigmoidoscopic appearance”) to those
based on endoscopic activity index scores.23
All of the IBD activity indices used in recent clinical trials
contain several subjective parameters, which may be re-
sponsible for some of the high placebo response rates seen
in several of these trials. Therefore, among other biologic
outcome parameters, endoscopic healing has been advocat-
ed in the evaluation of novel therapeutic agents in inflam-
matory bowel disease.
On the basis of currently available data, the optimal tim-
ing of assessments for mucosal healing is not clear. Random-
ized controlled trials on anti-TNF alpha in active Crohn's
disease have evaluated healing after different periods of
treatment (e.g., 4 weeks, 12 weeks, 26 weeks) in different
patient populations,24–26 and similar variability is seen in
UC trials (e.g., 6 weeks, 8 weeks, 16 weeks).10,27–30
Therefore, it seems premature to advocate routine endo-
scopic follow-up of all patients with Crohn's disease who
achieve clinical remission with medical therapy, but in pa-
tients presenting with persistent symptoms despite objective
clinical response, endoscopic assessment might be useful to
rule out post-inflammatory irritable bowel syndrome as a
cause of diarrhea and abdominal pain. Persistent or recurrent
symptoms suggestive of irritable bowel syndrome have been
reported in a substantial percentage of IBD patients with sus-
tained clinical and endoscopic remission.31 In addition, ileo-
colonoscopy is recommended during the first year after
surgery, when treatment decisions are tailored to the severity
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evidence that this strategy reduces the incidence/severity
of recurrence. Finally, mucosal healing is a predictor for sus-
tained clinical remission in patients who are stopping bio-
logics but continue immunosuppressives (thiopurines).32
In patients with ulcerative colitis, flexible sigmoidoscopy
is a reliable and generally well tolerated means for assessing
disease severity. Therefore, periodic endoscopy to evaluate
treatment effectiveness is an option that should be dis-
cussed with all patients with ulcerative colitis patients.
In conclusion, each of the methods used in clinical trials
to measure the endoscopic activity of Crohn's disease has
its own intrinsic limitations, and lack validated cut-offs,
thus reflecting the difficulties in arriving at a quantitative
measure of “healing”. In most of clinical trials on ulcerative
colitis, disease activity has been rated with composite clini-
cal and endoscopic scores. The accuracy of these indices is
limited by the wide spectrum of symptoms in patients with
distal or extensive UC, by overlaps in the endoscopic findings
associated with quiescent and mild-to-moderate disease,
and by the absence of formal validation. Therefore, no
robust recommendations for routine clinical practice can
be made on the basis of available evidence.
As noted earlier, the assessment of mucosal healing cur-
rently requires endoscopy, which is expensive, time-
consuming, and unpleasant for the patient, but new methods
are being developed for this purpose that should overcome
many if not all of these shortcomings, as discussed in part B
of this Workshop.• Mucosal healing is assessed by ileocolonoscopy or colonos-
copy according to the macroscopic appearance of the mu-
cosa. In light of the heterogeneity and the complexity of
mucosal lesions endoscopic indices of severity have been
developed.
• In Crohn's disease endoscopic indices present no validated
cut-off value for mucosal healing and the current definition
of mucosal healing employed in clinical trials and in clinical
practice is “disappearance of mucosal ulcerations”.
• Mucosal healing has been incorporated in the assessment
of treatment efficacy in ulcerative colitis. Current evi-
dence does not allow to clarify optimal timing of mucosal
healing assessment in inflammatory bowel disease.3. What drugs aremost likely to producemucosal
healing?
3.1. Crohn's disease
Clinical trials in the field of Crohn's disease have traditional-
ly evaluated treatment efficacy in terms of clinical symp-
toms rated with validated scoring systems. Well-defined
cut-offs for relapse and remission have been established
for the most widely used scoring systems, such as the Crohn's
disease activity index (CDAI), which has also been adapted
for use in pediatric patients, and the Harvey Bradshaw
index (HBI).14 Until recently, little emphasis has been placed
on mucosal healing as a treatment goal. It was regarded asunimportant and nearly impossible to achieve with the
treatments available until the 1990s. In the early 1990s, en-
doscopic evidence of mucosal healing was investigated in a
study designed to validate the CDEIS. Less than one third of
the patients treated for 7 weeks with high-dose corticoste-
roids displayed healing, and in almost 10% of the patients
the lesions actually worsened.33
At that time, the purine analogs were the only drugs
known to alter the course of Crohn's disease, diminishing
the need for steroids and promoting long-standing remission
and fistula healing.34 But at the end of the 1990s, therapy
with the azathioprine was also shown to be associated with
endoscopic evidence of mucosal healing in patients with
postoperative recurrence of Crohn's ileitis and those with
primary Crohn's ileocolitis.35,36 At this point, interest began
to grow in the concept of endoscopic healing, and its impact
on the course of the disease became increasingly clear.
Today–largely as a result of the introduction of biological
therapies for inflammatory bowel disease–mucosal healing
is regarded by many as an important measure of treatment
efficacy and an obligatory end point for studies aimed at
obtaining regulatory approval of treatments. It has been
included as a secondary or even primary endpoint in clinical
trials with biological agents, and it is also assuming an in-
creasingly important role in the follow-up of individual pa-
tients in clinical practice.
3.1.1. The mucosal healing capacities of drug therapies in
Crohn's disease
3.1.1.1. Corticosteroids. Although steroids are known to in-
duce acute clinical response and even remission in patients
with Crohn's disease, they do not seem to have any beneficial
effects on mucosal lesions or the likelihood of postoperative
recurrence of endoscopic lesions. Studies conducted by the
Groupe d'Etudes Thérapeutiques sur les Affections Inflamma-
toires Digestives (GETAID) showed that oral prednisolone
(1 mg/kg per day) produced clinical remissions in 92% of the
patients within 7 weeks, but only 29% of these patients
achieved endoscopic remission.Moreover, the clinical severity
of the disease displayed no correlation with the severity or ex-
tension (involved surface area) of endoscopic lesions.33,37 In a
small study in Sweden, glucocorticoids displayed high efficacy
in attenuating the symptoms of small-bowel Crohn's disease,
but once again this improvement was not accompanied by
any significant improvement in the small intestinal lesions ob-
served at endoscopy.38 More recently, Mantzaris et al. studied
77 patients with steroid-dependent forms of Crohn's ileocolitis
or proximal colitis who had achieved clinical remission on
conventional steroid therapy. After 1 year, only one out of
four of the 39 patients treated with budesonide (6–9 mg per
day) presented complete or near complete healing on
endoscopy.39
3.1.1.2. Thiopurines (azathioprine, 6-mercaptopurine)
Azathioprine's ability to induce mucosal healing in Crohn's dis-
ease was first demonstrated in 1997. D'Haens et al. studied 19
patients who had undergone ileocaecal resections for their
Crohn's disease, which were followed by severe recurrent ilei-
tis. Azathioprine therapy was maintained for at least
6 months after the patients had been completely weaned
off corticosteroids, and 15 of the patients were then
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ulator therapy produced sustained clinical remission in all 15
cases, and 6 (40%) exhibited endoscopic evidence of complete
mucosal healing in the neoterminal ileum. Eight others dis-
played near-complete healing with only superficial erosions
(n=5) or partial healing (n=3), and only 1 had no improve-
ment at all. On the basis of these findings, the authors sug-
gested that azathioprine should be the treatment of choice
for severe recurrent ileitis in patients with Crohn's disease.35
In another study, the same investigators endoscopically
evaluated 20 patients with Crohn's colitis or ileocolitis in
clinical remission achieved while they were taking azathio-
prine (for at least 9 months). None of the patients had
taken corticosteroids for at least 3 months before the endos-
copy. Complete to near-complete healing of the mucosa was
observed in the large bowel of 80% of the patients and at the
ileal level in up to 69%.36
The GETAID conducted a randomized, double-blind study
to identify the effects of azathioprine withdrawal on sus-
tained remission. Baseline ileocolonoscopy was performed
in 45 (54%) of the 83 patients. These patients had been in
clinical remission on azathioprine for at least 42 months.
Complete endoscopic remission defined as CDEIS=0 was
seen in 36% of the patients, although the mean CDEIS level
was rather low at baseline (mean=2.5).39 In another study,
sustained mucosal healing was investigated in patients who
had achieved clinical remission with standard corticosteroid
therapy. After 1 year of azathioprine therapy (2.0–2.5 mg/
kg), 83% of the patients presented evidence of complete or
near-complete healing, with a decrease in the mean CDEIS
from 7 to 0.55. In a multivariate logistic regression analysis,
initiation of AZA within 1 year of the Crohn's disease diagnosis
was the only factor that predicted complete endoscopic
healing.40In the step-up top down trial, on the contrary,
mucosal healing was observed in less than a third of patients
who were initially treated with steroids and maintained with
azathioprine.41 The reason for this discrepancy is not clear.
Reinisch et al. performed a prospective trial in patients with
postoperative recurrence of Crohn's disease comparing ami-
nosalicylates with azathioprine.42 An improvement in the
Rutgeerts score was observed in 63% of the patients on azathi-
oprine versus in 34% on aminosalicylates.
3.1.1.3. Methotrexate. In the late 1980s, Kozarek et al.
conducted a pilot study on the effects of methotrexate in
14 patients with Crohn's colitis, and after 12 weeks of treat-
ment 5 (36%) of the patients had colonoscopy-documented
mucosal healing.43 Later studies confirmed that methotrex-
ate was an effective drug for the induction and maintenance
of clinical remission.44–45 A single study assessed the effect
of methotrexate on mucosal healing in patients clinically
responding to the treatment.46 This observational study sug-
gested that methotrexate was inferior to infliximab
(p=0.008) or azathioprine (p=0.011) in inducing mucosal
healing.
3.1.1.4. Anti-TNF antibodies. The first anti-TNF antibody,
infliximab, has been evaluated in a number of multicenter
studies. The effects on mucosal healing were assessed in
substudies.
In 1999, D'Haens et al. reported the disappearance of
ulcers in the ileum in 74% of patients who had received asingle dose of infliximab 4 weeks before endoscopy, and
the rate of mucosal healing in the rectum was even higher
(96%). In the same study, decreases in the CDEIS were signif-
icantly correlated with drops in the CDAI.47 In a substudy of
the ACCENT I project, episodic and scheduled-treatment
infliximab regimens were compared in patients with Crohn's
disease who had a clinical response to a single infusion of the
biological agent (5 mg/kg).48 Patients randomized to the
scheduled-therapy regimen had fewer hospitalizations and
surgeries and higher rates of mucosal healing. At week 10,
complete mucosal healing was seen in 31% of the patients
in this group (versus 0% of those on episodic treatment),
and the difference was even more substantial at week 54
(mucosal healing rates of 50% and 7%, respectively). In addi-
tion, the mucosal healing rates were directly associated with
the number of hospitalizations, and no hospitalizations at all
were required in cases characterized by endoscopic remis-
sion at weeks 10 and 54. Nonetheless, this study found no
consistent relationship between mucosal healing and clinical
remission.6 Scheduled therapy also proved to be superior to
the episodic approach in a retrospective study of 214
patients with Crohn's disease, in which the initiation
of infliximab was associated with mucosal healing in 67.8%
of responders and complete mucosal healing in 45% of all pa-
tients. The likelihood of mucosal healing did not appear to
be related to the concomitant use of immunomodulators.7
In the SONIC trial, patients with active Crohn's disease who
had never been exposed to biological or immunomodulatory
treatment were randomized to azathioprine monotherapy,
infliximab monotherapy, or the two drugs combined. Steroid
tapering was obligatory after week 14. Endoscopy was
performed on all participants at the time of enrolment and at
week 26, the time point of the primary analysis. Mucosal
healing defined as the absence of ulcers was found in 44% of
the patients on combination treatment, 30% receiving inflixi-
mab monotherapy, and 16% of those on azathioprine monother-
apy. Statistically, the combo regimen was not superior to the
infliximab monotherapy group despite a strong trend.25 The
mucosal healing effects of other anti-TNF antibodies, adalimu-
mab and certolizumab pegol, have also been assessed. In the
EXTEND trial 129 patients with active Crohn's disease were
placed on induction treatment with adalimumab 160 mg fol-
lowed by 80 mg at week 2 and randomized to maintenance
treatment with 40 mg adalimumab or placebo every 2 weeks.
Endoscopic assessments were performed at baseline and at
weeks 12 and 52. At week 12, the complete mucosal healing
rate in the group on adalimumab maintenance therapy was
roughly twice as high as that observed in the placebo mainte-
nance group (27% versus 13%, respectively; p=0.056). At
week 52, 24% of adalimumab-treated patients still presented
complete healing but this finding was not observed in any of
the patients on placebo maintenance (pb0.001).26 In the
MUSIC study, all 89 patients received open-label induction
with certolizumab pegol (400 mg every 2 weeks for 3 doses
followed by 400 mg every 4 weeks), and endoscopies were per-
formed at baseline and at weeks 10 and 56. By week 10, the
mean CDEIS score was already significantly reduced (mean de-
crease: 42%, pb0.0001 versus baseline). Well over half (61%)
had score decreases of N5 points. However, only in 4 patients
all lesions had disappeared.49 Of note in the MUSIC trial CDEIS
criteria were used whereas in the ACCENT and EXTEND trial,
mucosal healing was judged by complete ulcer disappearance.
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biologic approach to the management of inflammatory
bowel diseases involves the suppression of leukocyte migra-
tion into inflamed intestinal tissues by blocking cellular ad-
hesion molecules. Natalizumab, a humanized monoclonal
antibody to α-4 integrin, has been shown to be effective
for the treatment of Crohn's disease,50 and it also induces
mucosal healing. In a small substudy of the ENACT-1 trial, 8
(22%) of the 37 patients with mucosal ulceration at study
entry achieved complete mucosal healing at week 10
compared with only 1 (8%) of the 13 in the placebo group.51
3.1.1.6. Enteral nutrition. A primary therapy in children
with Crohn's disease involves the use of an oral polymeric
diet as the sole source of nutrition, and this approach has
shown some efficacy in achieving mucosal healing.52,53 In a
randomized trial that included 37 children with active
Crohn's disease, the rate of mucosal healing in patients trea-
ted with the polymeric diet was significantly higher than
that achieved with corticosteroid therapy (74% versus 33%;
pb0.05).54
• Mucosal healing in Crohn's disease can be achieved, with
varying degrees of success and evidence, by means of cor-
ticosteroids, enteral nutrition (pediatrics), thiopurines,
methotrexate and biological agents (infliximab, adalimu-
mab, certolizumab pegol, natalizumab).
• Mucosal healing in Crohn's disease can be maintained with
thiopurines and biological agents (infliximab, adalimumab).3.2. Ulcerative colitis
In ulcerative colitis the inflammatory lesions are confined to
the mucosa, the most superficial layer of the colon, and the
disease almost always involves the distal colon, which is eas-
ier to examine with endoscopy. In the early 1990s, the re-
sults of a trial with 5-aminosalicylic acid (5-ASA) therapy
clearly showed that remissions documented by clinical and
endoscopic findings were likely to be longer-lasting than
those that were exclusively clinical.55 During the same peri-
od, another study demonstrated the positive impact of mu-
cosal healing on ulcerative colitis relapse rates. Flares
during the 12-month period following an episode of active
colitis were observed in only 4% of the patients with clinical
remission and mucosal healing and in 30% of those whose
clinical remission was accompanied by persistent mucosal le-
sions.56 Analogous pictures have emerged from a more re-
cent Italian study, where relapse rates at 1 year were 23%
in patients with clinical and endoscopic remission and 80%
in those who still had endoscopic lesions,10 and from the
ACT 1 and 2 trials. In the latter studies, rapid induction of
mucosal healing with infliximab resulted in a four-fold in-
crease in clinical remission rates at week 30.28 In light of
the documented impact of mucosal healing on the course
of ulcerative colitis, endoscopic assessments have been in-
corporated in the evaluation of drugs for ulcerative colitis.153.2.1. The mucosal healing capacities of drug therapies in
ulcerative colitis
3.2.1.1. 5-Aminosalicylic acid. A randomized study reported
in 1987 evaluated the efficacy of oral 5-ASA therapy (daily doses
of 4.8 or 1.6 g) in patients with mildly to moderately active ul-
cerative colitis. After 6 weeks of treatment, flexible proctosig-
moidoscopy showed complete and partial response rates of 24%
and 50%, respectively, in patients receiving the higher dose of 5-
ASA, whereas corresponding rates in the placebo group were
only 5% and 13%.19 Sandborn et al. analyzed the results of two
recent studies with Multi Matrix system (MMX) mesalazine and
found that rates of complete mucosal healing (defined as a sig-
moidoscopy score of 0) in patients treated with up to 8 weeks of
MMXmesalazine were roughly twice as high as those observed in
the placebo group (32% versus 16%, respectively).27 Similar mu-
cosal healing effects have been documented when 5-ASA is ad-
ministered topically: enemas containing 4 g 5-ASA and 100 mg
hydrocortisone were found to produce endoscopic healing
rates of 93% and 54%, respectively.57
3.2.1.2. Corticosteroids. The efficacy of steroids in con-
trolling ulcerative colitis was first documented in the 1950s
by Truelove and Witts. They reported mucosal healing
rates of 52% in patients who received high-dose steroid ther-
apy (cortisone 100 mg a day) for 6 weeks compared with only
32% of those treated for the same period with placebo.58
3.2.1.3. Azathioprine. Compared with 5-ASA, azathioprine
is significantly more effective in inducing clinical and endo-
scopic remission in corticosteroid-dependent ulcerative coli-
tis. This outcome was observed in over half of the AZA-
treated patients studied by Ardizzone et al., a therapeutic
gain of roughly 35% with respect to 5-ASA.59 The efficacy
of azathioprine was also documented in a study of 42 pa-
tients with corticosteroid-dependent or corticosteroid-
resistant ulcerative colitis. Complete endoscopic remission
was seen in 22 of 32 (69%) patients tolerating azathioprine
after 6 months. Ten patients were unable to tolerate azathi-
oprine, and 6 of these achieved complete mucosal healing
with methotrexate.60
3.2.1.4. Anti-TNF antibodies. The effects of infliximab in
active ulcerative colitis have been extensively investigated.
In the large controlled ACT-1 and ACT-2 trials, all partici-
pants were examined endoscopically at enrolment and
again at weeks 8 and 30. Fifty nine to sixty per cent of pa-
tients healed their mucosa on infliximab therapy at week
8, versus 32% on placebo (pb0.001). It should be noted
that the trial definition of mucosal healing was not “the ab-
sence of all lesions” but rather a Mayo endoscopic subscore
of 0–1, which means that healing sometimes included the
persistence of milder lesions. Using this definition, healing
rates at week 30 were 48%–53% in the infliximab groups ver-
sus 27% in patients treated with placebo (pb0.001), but
complete endoscopic healing rates (i.e., a Mayo score of 0)
were somewhat lower (25% and 28%–31% at weeks 8 and 30
vs. 8% and 9%, respectively), in the placebo group. Patients
who achieved complete mucosal healing also had better out-
comes: those who were healed at week 8 were 4 times more
likely to remain in remission until week 30 (43.8% vs. 9.5% in
those with persistent lesions at week 8). Most patients had
498 A. Armuzzi et al.repeat endoscopic investigations at week 54 during the
follow-up phase of this study, and maintenance of healing
was clearly demonstrated during continued infliximab
treatment.28
In the recently reported UC Success trial, which lasted
16 weeks, three different treatment regimens–azathio-
prine, infliximab, or infliximab plus azathioprine–were com-
pared in patients with moderate–severe ulcerative colitis.
None of the patients had been treated with biologic agents;
some had already been treated with azathioprine, but it had
been discontinued at least 3 months before enrolment.
Rates of mucosal healing in the patients who received inflix-
imab (55% with infliximab alone, 63% with infliximab plus
azathioprine) were significantly higher than that observed
in the azathioprine arm (37%; pb0.05).30
A very recent placebo-controlled study investigated the
efficacy of adalimumab to induce clinical remission in mod-
erately–severely active ulcerative colitis. Participants
were examined endoscopically at enrolment and after
8 weeks of therapy. Mucosal healing (defined as a Mayo en-
doscopic subscore of 0–1) was observed in 46.9% of those
treated with adalimumab 160/80 mg and 41.5% of those
who received placebo.29 The 52-week study assessed the ef-
ficacy of adalimumab for the induction and maintenance of
clinical remission in active ulcerative colitis. Participants
were examined endoscopically at enrolment and again at
weeks 8 and 52. Compared with placebo-treated patients,
those who received adalimumab had significantly higher
rates of mucosal healing (Mayo endoscopic subscore of 0–1)
at week 8 (41.1% versus 31.7%; p=0.03) and at week 52
(25% versus 15.4%; pb0.01). Sustained mucosal healing at
both weeks 8 and 52 was also significantly higher in the ada-
limumab group (18.5% versus 10.6%; p=0.01).61
3.2.1.5. Antibodies to cell adhesion molecules. In a
placebo-controlled trial of the anti-α4β7 integrin antibody
(MLN-02) in patients with active UC, Feagan et al. found
that 28% of patients who received 0.5 mg/kg of MLN02
were in endoscopic remission by week 6, more than twice
the rate (12%) observed among patients who received MLN-
02 at a dose of 2.0 mg per kilogram and over three times
higher than that (8%) observed in the placebo group.62
• Mucosal healing in ulcerative colitis can be achieved, with
varying degrees of success and evidence, by means of 5-
aminosalicylates (oral and topical), corticosteroids (oral
and topical), thiopurines, methotrexate and biological
agents (infliximab, adalimumab, MLN-02).
• Mucosal healing in ulcerative colitis can be maintained
with 5-aminosalicylates, thiopurines and biological agents
(infliximab, adalimumab).4. When to start treatment to achieve mucosal
healing?
The natural history of inflammatory bowel disease is charac-
terized by progressive complications. Therefore, the timingof initiation of therapy is of crucial importance in slowing
down this process, taking into consideration that a longer
disease duration inevitably leads to more irreversible dam-
age in spite of medical treatment.
Indirect proof of this principle comes from comparison of
studies on children and adults with inflammatory bowel dis-
ease. Earlier initiation of therapy is associated with higher
remission rates in pediatric Crohn's disease than it is in
adult patients, as shown by studies assessing thiopurines63,64
and TNF alpha blockers.65–68
In the “step-up/top-down” trial reported by D'Haens et
al.,41 129 patients with active, early-onset Crohn's disease
were randomly allocated to classic treatment (i.e., a
“step-up” approach consisting of remission induction with
corticosteroids followed by readministration of corticoste-
roids with azathioprine for new flares and possible treat-
ment with infliximab if active disease develops under
immunosuppressant therapy) or a more aggressive regimen
“top-down” approach in which combined-drug immunosup-
pression (infliximab plus azathioprine) was used from the
outset to induce remission. Two years after randomization,
complete mucosal healing (defined as complete disappear-
ance of ulcers) was observed in 73% of the patients in the
top-down group compared with only 30% of those in the
step-up treatment arm.
The effects of disease duration on deep remission in
Crohn's disease have been recently reported. In a subanalysis
conducted during the EXTEND trial,69 deep remission rates
after 52 weeks of adalimumab maintenance therapy were
significantly higher than those observed with placebo main-
tenance, with a trend toward relationship between deep re-
mission rates and disease duration in the adalimumab arm.
Similar findings have been reported in other chronic in-
flammatory diseases, such as rheumatoid arthritis. The
BeSt study, for example, showed that aggressive treatment
of early-stage rheumatoid arthritis can slow disease progres-
sion. In this multicenter trial, 508 patients were randomized
to disease-modifying anti-rheumatic drug monotherapy
(group 1), step-up combination therapy (group 2), initial
management with combination therapy that included ta-
pered high-dose prednisone (group 3), or initial management
with combination therapy that included infliximab (group 4).
After 1 year of treatment, radiographic damage in the latter
two groups was less severe than it was in patients managed
with monotherapy or step-up combination regimens,70 and
this advantage persisted over the next 2 years.71
• Combined immunosuppression is associated with higher
rates of mucosal healing than conventional therapy in
early-onset adult Crohn's disease.
• An indirect relationship between higher rates of mucosal
healing and Crohn's disease duration comes only from sub-
group analyses data. This point has not been formally in-
vestigated in ulcerative colitis.Can treatment step-up improve the chances of mucosal
healing and what strategies should be recommended after
mucosal healing has been achieved?
499Therapy and intestinal healing in IBDThere is no evidence that treatment intensification leads to
higher rates ofmucosal healing in patients with Crohn's disease.
In thosewith ulcerative colitis, however, the addition of enema
therapy to the oral drug regimen may improve healing in the
distal colon. A growing body of evidence supports the fact
that combined oral and rectal 5-ASA therapy in patients with
left-sided UC reduces the risk of relapse compared with mono-
therapy.72 A combination of oral and rectally administered
mesalazine for the treatment of extensive mildly to moderate-
ly active ulcerative colitis has resulted superior to oral mesala-
zine alone also for the treatment of extensive mildly to
moderately active ulcerative colitis.73 In a randomized,
double-blind study, remission rates at 8 weeks were 64%
among patients treated with oral mesalazine (4 g/day) plus
mesalazine enemas (1 g) compared with only 43% among
those taking oral mesalazine alone (p=0.03).
There are no prospective controlled data showing that
treatment intensification improves outcomes in patients
with persistent mucosal lesions in spite of sustained clinical
remission. As far as corticosteroids are concerned, available
data indicate that they do not have any effect in this setting.
The GETAID group reported that in patients with Crohn's dis-
ease prolonging prednisolone therapy (1 mg/kg body
weight/day) until the colonic mucosa was healed did not im-
prove the outcomes observed after the steroids were ta-
pered and finally discontinued.37 Moreover, relapse-free
intervals were similar patients who achieved clinical remis-
sion with and without endoscopic healing.
Healing of the mucosa has been associated with a prolon-
gation of the symptom-free interval in comparison with the
non-healed bowel, in an endoscopy substudy from D'Haens
et al.5 who followed-up patients from the ACCENT 1 study
and stratified them according to the degree of mucosal heal-
ing observed at the 54-week endoscopy. Irrespective of the
treatment arm (infliximab scheduled or episodic), patients
with complete or partial mucosal healing remained without
clinical relapse for a median of 20 and 19 weeks, respective-
ly. In contrast, those without mucosal healing developed
clinical relapse after a median of only 4 weeks.
In conclusion, in patients whose clinical remission is not
associated with mucosal healing or at least improvement of
the mucosal lesions, intensification of treatment is not cur-
rently recommended.
Limited information is available on the optimal duration of
immunosuppressive/biologic therapy in inflammatory bowel
disease patients in prolonged clinical remission. Open-label ex-
periences with anti-TNF alpha agents suggest that mucosal
healing at the time of treatment withdrawal may predict bet-
ter outcomes,whereas data on azathioprine showno influence.
Two studies have recently investigated relapse rates follow-
ing thiopurine withdrawal in patients with Crohn's disease or
ulcerative colitis who are in stable remission.74,75 Five-year
relapse rates indicated that only about one third of patients
with inflammatory bowel disease remain in remission after dis-
continuingmedication. However, neither of the studies provid-
ed endoscopic data on these patients. The GETAID azathioprine
withdrawal trial40 examined patients with Crohn's disease who
had been in clinical remission on azathioprine for at least
42 months. Treatment was continued for 18 months with
azathioprine or placebo. Kaplan–Meier estimates of the
18-month relapse rates were almost 3 times higher in the
placebo-treated group (21% versus 8% for azathioprine).Thirty-eight percent of the patients in the placebo group had
endoscopic disease activity when azathioprine was discontin-
ued (baseline), but the presence of mucosal ulceration was
not associated with the likelihood of disease relapse.
A substudy of the “step-up/top-down” trial looked at the
endoscopic appearance of the gut mucosa after 2 years of
treatment as a possible predictor of disease outcome in the
following 2 years.4 At the end of year 2, 49 of the trial par-
ticipants underwent ileocolonoscopy, and the presence of
complete mucosal healing during that examination was the
only predictor of sustained corticosteroid- and infliximab-
free clinical remission during years 3 and 4 (p=0.036; OR
4.35, 95% CI 1.1–17.2).
Finally, the STORI trial provides data about factors associ-
ated with clinical relapse following infliximab discontinua-
tion in patients with Crohn's disease who had been treated
with infliximab plus azathioprine and were in stable remis-
sion for at least 6 months. Twelve months after infliximab
was discontinued, clinical relapse was observed in 45 of
the 115 patients with luminal Crohn's disease, and one of
the predictors of this outcome was the absence of mucosal
healing when the drug was withdrawn.32
• Treatment intensification to achieve mucosal healing in
patients with Crohn's disease in clinical remission but not
endoscopically healed is not recommended because of
lack of evidence.
• In patients with ulcerative colitis, the addition of topical
therapy to the oral regimen increases mucosal healing rates.
• Mucosal healing in Crohn's disease assessed at the time of
anti-TNF alpha discontinuation is associated with better out-
comes. Conversely, data on azathioprine show no influence.
This point has not been formally investigated in ulcerative
colitis.5. Conclusions
There is a growing body of evidence that supports the impor-
tance of mucosal healing in both Crohn's disease and ulcera-
tive colitis. In the era of biological therapy for inflammatory
bowel disease, this parameter is emerging as a reliable pre-
dictor of disease control reflected by fewer surgical inter-
ventions and higher remission rates in Crohn's disease and
lower colectomy rates and longer periods of disease control
in ulcerative colitis. With newer forms of therapy, rapid,
complete endoscopic remission is an attainable goal.
Additional research is needed to determine whether/how
the endoscopic appearance of the gut mucosa should be
used in the therapeutic decision-making process, but its as-
sessment is already an essential component of clinical prac-
tice and studies in the field of inflammatory bowel disease.
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